Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: Results from the International Breast Magnetic Resonance Consortium (IBMC) trial
✍ Scribed by Constance D. Lehman; Jeffrey D. Blume; David Thickman; David A. Bluemke; Etta Pisano; Christiane Kuhl; Thomas B. Julian; Nola Hylton; Paul Weatherall; Michael O'Loughlin; Stuart J. Schnitt; Constantine Gatsonis; Mitchell D. Schnall
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 151 KB
- Volume
- 92
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Objective:
To estimate the added cancer yield of magnetic resonance imaging (mri) over mammography in the contralateral breast of patients with a recent diagnosis of breast cancer.
Methods:
We conducted a prospective, international study of mammography and mri in women with a recent diagnosis of unilateral breast cancer. each subject received a mammogram, clinical breast exam (cbe), and mri of the unaffected breast within a 90 day time period. definitive diagnosis of suspicious findings was determined through biopsy and central pathology review.
Results:
Of the 103 eligible women included in study analyses, mri detected 4 cancers in the contralateral breast while mammography detected none. mri resulted in 12% (95% ci, 6%-20%) of women recommended for biopsy and 10% of women undergoing additional biopsy. the added cancer yield of mri was 4% (95% ci, 1%-10%) and the positive predictive value of an abnormal mri was 33% (95% ci, 10%-65%). forty percent (4/10) of the biopsies performed based on the mri recommendation were positive for malignancy.
Conclusion:
In women with a recent breast cancer diagnosis, approximately 4% will have an otherwise occult invasive breast cancer detected in the opposite breast by mri alone.